1/14
08:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
1/9
07:00 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
12/14
01:26 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at
Wall Stre
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at
Wall Stre
11/22
08:12 am
mnpr
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
Low
Report
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
11/14
07:22 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
11/14
05:16 am
mnpr
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]
High
Report
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]
11/13
08:38 am
mnpr
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]
Medium
Report
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]
11/13
08:00 am
mnpr
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
Medium
Report
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
11/11
07:17 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/25
12:09 pm
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.